Citi will downgrade Prime Medicine (PRME) to neutral and reduce PT to $1.50 due to market uncertainty
On Tuesday, City will be holding Prime Medicine Inc. (NASDAQ:prme) From buying to neutral valuation, it will significantly reduce its price target from $10 to $1.50. Citi said the adjustment … Read More